TY - JOUR
T1 - The importance of solvation in the design of ligands targeting membrane proteins
AU - González, Angel
AU - Murcia, Marta
AU - Benhamú, Bellinda
AU - Campillo, Mercedes
AU - López-Rodríguez, María L.
AU - Pardo, Leonardo
PY - 2011/3/1
Y1 - 2011/3/1
N2 - A crucial contribution to the ligand-receptor binding affinity is, in addition to their electrostatic and van der Waals interactions, the desolvation of the ligand. This is of special relevance in membrane proteins because the ligand has to be transferred from the aqueous environment to the transmembrane binding site crevice. Herein we report the synthesis of new serotonin 5-HT 4 receptor antagonists that replace a key carbonyl group by the thiocarbonyl bioisoster. This modification enhances experimental 5-HT 4 receptor binding affinities by as much as 91 times. Free energy perturbation calculations have shown that the significant decrease of the penalty of desolvation, facilitating the entrance of the ligands into the binding site crevice, compensates for the weaker ligand-receptor interaction. © 2011 The Royal Society of Chemistry.
AB - A crucial contribution to the ligand-receptor binding affinity is, in addition to their electrostatic and van der Waals interactions, the desolvation of the ligand. This is of special relevance in membrane proteins because the ligand has to be transferred from the aqueous environment to the transmembrane binding site crevice. Herein we report the synthesis of new serotonin 5-HT 4 receptor antagonists that replace a key carbonyl group by the thiocarbonyl bioisoster. This modification enhances experimental 5-HT 4 receptor binding affinities by as much as 91 times. Free energy perturbation calculations have shown that the significant decrease of the penalty of desolvation, facilitating the entrance of the ligands into the binding site crevice, compensates for the weaker ligand-receptor interaction. © 2011 The Royal Society of Chemistry.
U2 - https://doi.org/10.1039/c0md00258e
DO - https://doi.org/10.1039/c0md00258e
M3 - Article
VL - 2
SP - 160
EP - 164
JO - MedChemComm
JF - MedChemComm
SN - 2040-2503
ER -